In Depth 11 May 2023
Battling food allergies: emerging immunotherapies
While for most individuals, picking a restaurant to dine at could simply be based on what they might be craving at the moment, for about one to five per cent…
DBV Technologies
- Latest Posts
Best in Biotech 4 Nov 2022
Get to know 15 of the best biotech companies in Paris
Paris may attract tourist masses, but it also attracts a lot of biotech enthusiasts. In this guide, we explore 15 interesting biotech companies in Paris. Paris is one of the…
News and Trends 14 Apr 2021
DBV Battles Aimmune for Share of Peanut Allergy Treatment Market
Last year, the FDA rejected DBV Technologies’ peanut allergy treatment and approved that of its rival Aimmune. After recent talks with the FDA and EMA, DBV has laid out a…
Best in Biotech 11 Jan 2021
The 21 European Biotech Companies To Watch in 2021
As we enter 2021, the biotech industry is already bustling with activity. Here’s a list of 21 European biotech companies likely to make a big splash in the biotechnology sector…
ADVERTISEMENT
News and Trends 6 Aug 2020
DBV Technologies’ Peanut Allergy Patch Suffers FDA Setback
A request for market approval of a skin patch developed by French biotech DBV Technologies to treat peanut allergy has been turned down by the FDA, which has requested more…
News and Trends 25 Mar 2020
DBV Technologies’ Peanut Allergy Treatment Hits FDA Setback
French biotech DBV Technologies’ bid for the US approval of a skin patch to treat nut allergies could be delayed as the FDA requested more information on the patch’s efficacy.…
News and Trends 29 May 2018
This Immunotherapy Could Be The First to Treat Milk Allergy in Children
DBV Technologies has shown in a Phase II trial that its skin patch could desensitize over 60% of children with strong milk allergy. DBV Technologies, one of the largest public biotechs…
News and Trends 27 Feb 2018
DBV Technologies’ Milk Allergy Patch Helps Kids in a Phase II Trial
DBV Technologies' candidate could be the first treatment for allergies to cow milk after its Viaskin Milk skin patch achieved positive Phase II results. DBV Technologies is developing a skin…
News and Trends 20 Nov 2017
After Failed Trial, French Biotech Gets Good News for its Peanut Allergy Therapy
DBV Technologies has positive safety data supporting the approval of a treatment for peanut allergy in children, though its efficacy is uncertain. DBV Technologies saw its stock go down by 45%…
News and Trends 23 Oct 2017
Peanut Allergy Trial Fails but French Biotech Keeps Pushing for Approval
DBV Technologies plans to go ahead with its peanut allergy treatment despite its failure to meet a primary endpoint in Phase III. Last Friday, DBV Technologies released the results of…
ADVERTISEMENT
News and Trends 2 Aug 2017
French Biotech May Save Toddlers from Life-Threatening Peanut Allergy
The first French biotech to NASDAQ, DBV, is expanding the patient group for its promising peanut allergy treatment to include toddlers. DBV Technologies' Phase IIb results of its peanut allergy therapy,…
Best in Biotech 15 Mar 2017
What are the Best Countries to Recruit Biotech Talents in 2017?
Before the “who to recruit” phase, an important question is “where?” We ran through the top countries in which to look for talent in biotech and had a look at what…
Infographics 21 Feb 2017
Infographic: The Biggest Biotech Company in Each European Country
We had a look into European biotech and created a map with the biggest biotech companies in each country, according to their market cap. Biotech is one of the biggest…
Best in Biotech 22 Dec 2016
The 10 Biggest Clinical Success Stories of 2016 in European Biotech
What are the most impressive advances in medical biotechnology this year? From cancer to peanut allergy, here's a list of the best success stories of 2016. Biotech is becoming a…
News and Trends 25 Oct 2016
The First Peanut Allergy Therapy might soon hit the Shelves
DBV Technologies announced outstanding Phase IIb results for Viaskin Peanut, which could be the first-ever commercial peanut allergy therapy in the near future. However, competition is stiff. DBV Technologies, the…
News and Trends 6 Sep 2016
“This Phase I could Pioneer Needle-free Vaccines”, DBV’s CEO
How annoying are needle vaccinations? Very ... But the French billion-euro Biotech DBV Technologies wants to bring a paradigm shift via its Anti-allergy Patch platform! I got to chat with…
ADVERTISEMENT
News and Trends 12 Jul 2016
Which European Biotechs made it to the Billion-Euro Club in 2016?
Europe has a lot of successful Biotech companies, but which of those are worth a billion euros or more? I did a previous version of this article last year and now I explore how…
News and Trends 31 May 2016
DBV Technologies: “This is our First and most Significant Partnership signed”
The billion-euro Biotech from Paris DBV Technologies just signed a €100M deal with Nestlé Health Science to develop a new diagnostic test of Milk allergies. This is the first deal…
News and Trends 14 Mar 2016
DBV: “These Additional Results Confirm our Potential of solving the Peanut Allergy problem Worldwide”
DBV Technologies (Paris) was just under the spotlight in Los Angeles at the biggest allergy convention worldwide (2016 AAAAI Annual Meeting). Their Viaskin skin patch could potentially eradicate peanut allergies for patients altogether...…
News and Trends 23 Feb 2016
7 Trendy European Biotechs Listed on the NASDAQ in 2016
Here are 7 European Biotechs listed on the NASDAQ we thought were worth mentioning in more depth; location, market cap and brief financial and R&D backgrounds. NASDAQ is the second-largest Stock…
